DESCRIPTION

Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.

Benefits to authors
We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.

Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center.

IMPACT FACTOR

2018: 4.117 © Clarivate Analytics Journal Citation Reports 2019

ABSTRACTING AND INDEXING

Scopus
Embase
CINAHL
Chemical Abstracts
Ovid
EBSCOhost
PubMed/Medline

EDITORIAL BOARD

Editor-in-Chief
Antoinette Wozniak, Pittsburgh, Pennsylvania, United States
Senior Associate Editors
Shirish Gadgeel, Detroit, Michigan, United States
Laurie Gaspar, Aurora, Colorado, United States
Friedrich Knollmann, Philadelphia, Pennsylvania, United States
Jonathan Riess, Sacramento, California, United States
Inderpal (Netu) S. Sarkaria, Pittsburgh, Pennsylvania, United States

Associate Editors
David T. Cooke, Sacramento, California, United States
Walter J. Curran Jr., Philadelphia, Pennsylvania, United States
Corey J. Langer, Philadelphia, Pennsylvania, United States
Tony S. Mok, Hong Kong, China
Mary Redman, Seattle, Washington, United States
Giorgio V. Scagliotti, Torino, Italy

Publisher
Angela Carmona, Philadelphia, Pennsylvania, United States

Editorial Board
Alex A. Adjei, Buffalo, New York, United States
Area of Expertise: Medical oncology, clinical pharmacology, drug development, translational research
Arya Amini, Duarte, California, United States
Radiation Oncology
Paul Baas, Amsterdam, Netherlands
Development of new therapies and the treatment of lung cancer and malignant mesothelioma
Paolo Bironzo, Torino, Italy
Immunotherapy and solid tumors
Collin Blakely, San Francisco, California, United States
Medical Oncology; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung
Michael Boyer, Camperdown, Australia
Conjoint Chair of Medical Oncology (Thoracic Oncology); new anticancer drugs for the treatment of lung cancer
Elisabeth Brambilla, Grenoble, France
lung tumor pathology
Paul A. Bunn, Aurora, Colorado, USA
Translational research in lung cancer; identifying novel diagnostics and treatment strategies
Timothy Burns, Pittsburgh, Pennsylvania, United States
Medical Oncology; KRAS mutant non-small cell lung cancer; EGFR mutant lung cancer
Brett Carter, Houston, Texas, United States
Imaging; Diagnostic Imaging; Interventional Radiology
Suzanne Dahlberg, Boston, Massachusetts, United States
Biostatistics & Computational Biology
Justin Gainor, Boston, Massachusetts, USA
Design of clinical trials evaluating novel therapeutics for molecularly-defined subsets of non-small cell lung cancer; translational research
Giuseppe Giaccone, Georgetown, Maryland, United States
Developmental therapeutics; thymoma
Glenwood Goss, Ottawa, Ontario, Canada
Early cancer drug development and thoracic oncology
Koichi Goto, Chiba, Japan
Primary lung cancer, mediastinal tumors, and pleural tumors
John Heymach, Houston, Texas, United States
Molecular drivers of lung cancer, identification of predictive biomarkers of drug sensitivity, and identification of mechanisms of therapeutic resistance and novel strategies to overcome resistance
Fred Hirsch, Denver, Colorado, United States
Niki Karachaliou, Barcelona, Spain
Medical Oncology; Translational Research
Edward Kim, Charlotte, North Carolina, United States
Chair of the Department of Solid Tumor Oncology; thoracic cancer and cancers of the head and neck; molecular prognostication for lung cancer
Feng-Ming (Spring) Kong, Cleveland, Ohio, United States
Radiation Oncology
Zhang Li, Guangzhou, China
Clinical trials in lung cancer, new therapeutics, molecular markers
Philip Mack, Davis, California, United States
Molecular biology and molecular pharmacology studies; basic and translational research; molecular and cellular effects of novel anticancer agents

Christian Manegold, Mannheim, Germany
Surgery

Tetsuya Mitsudomi, Osaka, Japan
Thoracic Surgery

Daniel Morgensztern, Saint Louis, Missouri, United States
Medical Oncology; Thoracic malignancies

Sai-Hong Ignatius Ou, Irvine, California, United States
Nasopharyngeal Carcinoma, Head and Neck Cancer, Thoracic malignancies, Esophageal carcinoma, Targeted therapy

David Planchard, Villejuif, France
Genomic analysis (and high-throughput technologies) to drive lung cancer patients to specific targeted agents

Suresh Ramalingam, Atlanta, Georgia, United States
Immune checkpoint inhibitors and improving outcomes for patients with EGFR mutation

Jordi Remon, Barcelona, Spain
Medical Oncology; genomic characterization by liquid biopsies, as well as, the improvement in therapeutic strategies in thymic malignancies and mechanisms of resistance in small cell lung cancers

Jill Siegfried, Rochester, Minnesota, United States
Pharmacology; lung cancer biology and experimental therapeutics, focusing on targeting growth factors and hormone signaling that control lung cancer cell proliferation to treat lung cancer, and how immunotherapy can be enhanced by targeted therapy

Thomas Stinchcombe, Durham, North Carolina, United States
Clinical care, clinical trials, and developing new therapies; Medical Oncology

Stephen Swisher, Houston, Texas, United States
Thoracic and Cardiovascular Surgery

Masahiro Tsuboi, Shinjuku-Ku, Japan
Thoracic Surgery

Liza Villaruz, Pittsburgh, Pennsylvania, United States
Medical Oncology; lung cancer and thoracic malignancies

Jie Wang, Beijing, China
Clinical trials in lung cancer, new therapeutics, molecular markers

Yi-long Wu, Guangzhou, Guangdong, China
Clinical trials in lung cancer, new therapeutics, molecular markers
**GUIDE FOR AUTHORS**

**INTRODUCTION**

Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.

**Types of paper**

**Reviews:** Review articles collate, describe, and evaluate prior publications of important clinical subjects, accompanied by critical analysis leading to rational conclusions. These Reviews should contain very little, if any, original data from an author's own study; however, such data can be used to support the overall thesis of the article. We also accept targeted mini-reviews that cover specific topics or therapies.

**Mechanics:** Review articles should contain a short abstract stating the goal of the review, an introduction, discussion, and conclusion. We recommend that Review articles contain 2000-10,000 words, ≤ 7 figures and/or tables, and 50-120 references.

**Perspectives:** Perspectives are more focused than reviews and seek to review a topic from a particular view or opinion. Perspectives should review a particular field to identify outstanding issues and/or challenges and propose new hypotheses or directions. A Perspective may highlight emerging science, controversial opinions, or issues within the field and seek to address these controversies. They may be accepted from a single individual or a team.

**Mechanics:** Perspectives should contain a short abstract stating the goal of the review, an introduction, discussion, and conclusion. We recommend that Perspective articles contain 2000-8000 words, ≤ 7 figures and/or tables, and 45-90 references.

**Original Studies:** Original Studies articles present results of original clinical and/or translational (basic research with clinical applications) research. This article focuses on new data collected by the author(s) during the course of a clinical or preclinical trial, although other studies may be cited for support. The Original Study should contain the following sections: Title Page, Structured Abstract, Introduction, Patients (or Materials) and Methods, Results, Discussion, and Conclusion.

**Mechanics:** Original Studies should contain a MicroAbstract and a structured abstract with the following sections: Background (or Purpose), Patients (or Materials) and Methods, Results, and Conclusion. Original Studies should also contain a short clinical practice points section after the conclusion of the manuscript. We recommend that Original Studies contain 2000-8000 words, ≤ 7 figures and/or tables, and 30-60 references.

**Case Reports:** Case Reports of educational value may describe a single case or a small series of cases. Case Reports should draw attention to important clinical situations, unusual clinical phenomena, new treatment protocols, or new complications in a single patient or in a small number of patients. Case reports may also cover novel diagnostic imaging techniques, e.g., MRI, CT, PET, SPECT. Modalities for diagnostic purposes, on outcome according to the pathologic grade or to monitor distant lesions, are of interest to the readership.

**Mechanics:** Case Reports should contain the following sections: Title Page, Clinical Practice Points, Introduction, Discussion, and Conclusion. We recommend that Case Reports contain 500-1500 words, 1-2 figures and/or tables, and 15-30 references. Imaging articles dealing with individual cases contain 500-1500 and that case series contain 2000-3000 words, 3-5 figures and/or tables, and 30-45 references.

**Current Trial Reports:** Current trials of educational value describe the rationale, criteria, treatment plan, and anticipated results of a planned or ongoing trial. The format for this article may follow a format similar to that of an Original Study (see above); however, because this type of article discusses an ongoing or planned trial, conclusive data regarding outcomes should not be included.

**Mechanics:** Current Trial Reports should contain the following sections: Title Page, Structured Abstract, Introduction, Discussion, and Conclusion. We recommend that Current Trial Reports contain 500-1500 words, 1-2 figures and/or tables, and 5-15 references.
Clinical Commentary: Clinical Commentaries focus on clinical topics that are novel or controversial and require rapid dissemination. These articles may also highlight treatment options, protocols, and/or novel case treatments. Authors who wish to submit an unsolicited Commentary should send a brief abstract to the Editor-in-Chief prior to submission in order to receive approval.

Mechanics: Commentaries should contain the following sections: Title Page, Introduction, Discussion, and Conclusion. We recommend Commentaries contain 1000-2000 words, 1-2 figures and/or tables, and 15-30 references.

Letters to the Editor: Letters to the Editor should focus on articles published within the journal during the last 12 months. These letters should be timely and seek to engage the authors of the original article in discussion. The authors of the original article will be asked to respond to a Letter to the Editor, commenting on their article. The Letter to the Editor and the Reply to the Letter to the Editor will be published together.

Mechanics: We recommend that letters contain 500-1000 words, and they may contain 1-2 figures and/or tables and 5-15 references.

Other Items: The journal also publishes highlights/reports of scientific meetings and book reviews. Please contact the editorial office for further information.

Contact details for submission
If you have questions regarding any of the requirements for submitting a manuscript to the Journal, please contact the editorial office at clc@elsevier.com.

Submission checklist
You can use this list to references mentioned out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:
- E-mail address
- Full postal address

All necessary files have been uploaded:
Manuscript:
- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print

Graphical Abstracts / Highlights files (where applicable)
Supplemental files (where applicable)

Further considerations
- CLC will no longer accept manuscripts whose titles are phrased in the form of a question; all manuscript titles should be non-interrogatory in nature
- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- Relevant declarations of interest have been made
- Journal policies detailed in this guide have been reviewed
- Minimum of 3 suggested reviewers, with institutional affiliations, and email addresses

For further information, visit our Support Center.

BEFORE YOU BEGIN

Ethics in publishing
Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication.
Editorial Policies and Practices

Human Subject Studies: It is the responsibility of the authors to assure that all clinical investigations detailed in manuscripts submitted to the journal are conducted in accordance with the Declaration of Helsinki and to document that these studies have been approved by the appropriate institutional human research committee. Identifying information within written descriptions, photographs or pedigrees should not be published. If such information is included as essential scientific information, the authors must submit written consent of patient or guardian to publish such photographs in the print and electronic versions of the journal.

Animal Studies: It is the responsibility of the authors to assure that their experimental procedures are in compliance with the guiding principles in the "Care and Use of Animals" (published each month in the Information for Authors of the American Journal of Physiology or available online at http://www.nap.edu/books/0309053773/html/) and to document that these studies were approved by the appropriate institutional animal care and oversight committee.

Declaration of interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. More information.

Financial interests should be disclosed to the Editor-in-Chief in the cover letter and on a separate conflict of interest page in the manuscript.

Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.

Preprints
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).

Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

Author contributions
For transparency, we encourage authors to submit an author statement file outlining their individual contributions to the paper using the relevant CRediT roles: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing. Authorship statements should be formatted with the names of authors first and CRediT role(s) following. More details and an example
**Authorship**
Clinical Lung Cancer requires that all persons listed as an author on a manuscript submitted to or published in the journal meet the ICMJE criteria for authorship. The ICMJE recommends that authorship be based on the following 4 criteria: (Available at: http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html#two Section 2, para 1-2) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND. Drafting the work or revising it critically for important intellectual content; AND. Final approval of the version to be published; AND. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. In addition to being accountable for the parts of the work he or she has done, an author should be able to identify which co-authors are responsible for specific other parts of the work. In addition, authors should have confidence in the integrity of the contributions of their co-authors.

**Changes to authorship**
Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only **before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors **after** the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

**Copyright**
Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author's choice of user license.

**Author rights**
As an author you (or your employer or institution) have certain rights to reuse your work. More information.

Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.

**Role of the funding source**
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

**Open access**
Please visit our Open Access page for more information.
Elsevier Researcher Academy

Researcher Academy is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's Author Services.

Informed consent and patient details

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained. For more information, please review the Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

Submission

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Submit your article

Please submit your article via http://www.ees.elsevier.com/clc/.

Full instructions for online submission are available on the Elsevier EES submission site. Upon receipt of a manuscript, an e-mail message will be sent to the corresponding author confirming receipt of the paper. If you do not receive this confirmation within 48 hours, contact the editorial office cllc@elsevier.com to confirm receipt.

Referees

Each submitted manuscript is required to include at least three suggested reviewers, with affiliations, and email addresses. Authors should consider carefully their suggested reviewers. Suggested reviewers should not have a conflict of interest for the submitted manuscript, nor have substantial ties to the authors of the manuscript. Email addresses must be from the suggested reviewer's institutional affiliation, not a non-specific, generic email address. Suggested reviewers should have expertise in the subject matter of the submitted manuscript. For more details, visit our Support site. Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.

Review Process

The Editorial team may triage a manuscript via initial review by the editorial staff, including the Editor and at least one Associate Editor, to ensure the paper meets certain criteria. Reasons for triage may include: insufficient direct relevance to the scope of the Journal, inadequate or unethical methodology, inadequate statistical power or assessment, insufficient innovation or contribution to the advancement of the field. All other manuscripts will undergo the full peer review process, being referred to an Associate Editor, who will identify reviewers with the expertise to review the paper. At each Associate Editor's discretion, any manuscript may be referred specifically for statistical review relating to the appropriateness or otherwise of statistics used, adjustment for multiple comparisons, sample size issues and the like. Manuscripts with inadequate or inappropriate statistics will not be accepted. Authors are encouraged to suggest names of appropriate reviewers (include phone/fax/address/e-mail for each reviewer suggested) and may also request that a specific reviewer not be used.
Authors will receive a full response on their manuscript detailing any changes required by the Reviewers and Editorial team and the decision about the acceptance or otherwise of the manuscript. Only authors listed on the manuscript may receive information about a manuscript.

Authors who wish to object to an unfavorable decision must do so within two months of notification of a decision. Please note all communications must be addressed to the editorial office via email cllc@elsevier.com. Any materials or communications sent to the Editor or Associate Editors will incur delays because they will be forwarded to the central Editorial Office for handling.

**PREPARATION**

**Manuscript Format**

CLC will no longer accept manuscripts whose titles are phrased in the form of a question; all manuscript titles should be non-interrogatory in nature.

We wish to emphasize the importance of clarity and succinctness of the presentation of material: Please respect the relevance of all material to the Introduction, Methods, Results and Discussion and avoid unnecessary repetition. Do not repeat the results and conclusions in the Introduction. Conclusions should NOT be stated throughout the Results section. Results should not be restated throughout the Discussion section. Avoid simply restating the Results in the Discussion rather than explaining how each result advances the overall conclusions of the study. The final part of the Discussion should refer back to the rationale for the study and explain how the findings have advanced the area.

We strongly recommend authors employ the format and guidelines detailed below.

**Abbreviations and Nomenclature:** Abbreviations and nomenclature should follow the recommendations of the International Union of Pure and Applied Chemistry and the International Union of Biochemistry [see http://www.chem.qmul.ac.uk/iupac/jcbn/]. The International system of Units (SI units) is recommended. It is desirable to include appropriate conversion factors to aid the reader.

**Order**

Title Page, Conflict of Interest Page, MicroAbstract (Original Studies), Abstract, Introduction, Materials and Methods, Results, Discussion, Conclusion, Clinical Practice Points, Acknowledgments, References, Tables, Figures. (Number ALL pages consecutively)

**Use of word processing software**

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

**Article structure**

**Subdivision - unnumbered sections**

Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading should appear on its own separate line. Subsections should be used as much as possible when cross-referencing text: refer to the subsection by heading as opposed to simply 'the text'.

**Introduction**

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.
Material and methods
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

Results
Results should be clear and concise.

Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Appendices
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
  • CLC will no longer accept manuscripts whose titles are phrased in the form of a question; all manuscript titles should be non-interrogatory in nature.
  • Author names and affiliations. Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lowercase superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
  • Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.
  • Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Highlights
Highlights are optional yet highly encouraged for this journal, as they increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the examples here: example Highlights.

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

Abstract
The entire Abstract should not be more than 250 words. The abstract should be self-explanatory without reference to the text. Original Contributions should include a structured abstract with the following sections: Introduction/Background, Materials (or Patients) and Methods, Results, and Conclusion.
MicroAbstract (Original Studies)
Each manuscript should start its abstract with a microabstract limited to 3-4 sentences (60 words). The microabstract is not included as part of the structured abstract and will be excerpted in the Table of Contents to each issue. It may also be used for wider circulation. It should describe the: Area and reason for the study Approach taken including sample size aspects Overall result General significance of the findings All information should be accessible to a non-expert audience.

Clinical Practice Points (Original Studies, Case Reports)
Authors should complete a short summary (250 words or less) detailing the clinical importance of the study. The summary should address the following questions:
• What is already known about this subject?
• What are the new findings?
• How might it impact on clinical practice in the foreseeable future?

Graphical abstract
Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site. Authors can make use of Elsevier's Illustration Services to ensure the best presentation of their images and in accordance with all technical requirements.

Keywords
Five keywords should be listed at the bottom of the abstract page. Words used in the title of the article or journal title may not be used as keywords.

Abbreviations
Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article. Abbreviations should follow the recommendations of the International Union of Pure and Applied Chemistry and the International Union of Biochemistry [see http://www.chem.qmul.ac.uk/iupac/jcbn/].

Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Units
Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.
Math formulae
Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the published version.
• Submit each illustration as a separate file.
• Ensure that color images are accessible to all, including those with impaired color vision.

A detailed guide on electronic artwork is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.
Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/halftone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.

Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF) or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) in addition to color reproduction in print. Further information on the preparation of electronic artwork.

Illustration services
Elsevier's Author Services offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

Please use small non-bold, non-italic capital letters and place them in Arial font when using figure headings/labels. Authors who would like to test their figures for publication quality should use Digital Expert: http://dx.sheridan.com/.
Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference links
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal of Geophysical Research, https://doi.org/10.1029/2001JB000884. Please note the format of such citations should be in the same style as all other references in the paper.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link: http://open.mendeley.com/use-citation-style/clinical-lung-cancer

When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

Reference style

Text: Indicate references by (consecutive) superscript arabic numerals in the order in which they appear in the text. The numerals are to be used outside periods and commas, inside colons and semicolons. For further detail and examples you are referred to the AMA Manual of Style, A Guide for Authors and Editors, Tenth Edition, ISBN 0-978-0-19-517633-9.

List: Number the references in the list in the order in which they appear in the text.

Examples:
Reference to a journal publication:
Reference to a journal publication with an article number:
Reference to a book:
Reference to a chapter in an edited book:
Reference to a website:
Reference to a dataset:


Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.

Video
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file’s content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For
more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

**Data visualization**
Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

**Supplementary material**
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

**Research data**
This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

**Data linking**
If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

**Mendeley Data**
This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to Mendeley Data. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the Mendeley Data for journals page.

**Data statement**
To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.
Acceptance and Online Only Publication
The editor reserves the right to schedule your manuscript for print or online only publication. All manuscripts will appear in a printed table of contents; however, some papers may only be available online due to print page restrictions.

AFTER ACCEPTANCE

Online proof correction
To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.
We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's Author Services. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.
You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2018 Elsevier | https://www.elsevier.com